ThermoGenesis Holdings to Announce Financial Results for the Year Ended December 31, 2022 and Provide a Corporate Strategic Update

Rhea-AI Summary

ThermoGenesis Holdings, Inc. (THMO) announced it will release its financial results for the year ending December 31, 2022, on March 30, 2023. The release will include a corporate strategic update following the market close. A conference call is scheduled for the same day at 1:30 p.m. PT (4:30 p.m. ET), accessible via phone or live webcast. ThermoGenesis specializes in automated technologies for CAR-T and other cell-based therapies, offering solutions for automated clinical biobanking and immuno-oncology. Investors can access a webcast replay on the company’s website for three months following the event.

Positive

• Scheduled release of financial results indicates transparency and engagement with investors.
• Focused on CAR-T and cell-based therapies, suggesting potential growth in the biopharmaceutical market.

Negative

• None.

Conference Call to be Held on March 30, 2023

RANCHO CORDOVA, Calif., March 28, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.

To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts/.

A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact: 
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact: 
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com 

 

View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-year-ended-december-31-2022-and-provide-a-corporate-strategic-update-301783044.html

SOURCE ThermoGenesis Holdings, Inc.

FAQ

When will ThermoGenesis announce its financial results for 2022?

ThermoGenesis will announce its financial results on March 30, 2023.

What time is the ThermoGenesis conference call on March 30, 2023?

The conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on March 30, 2023.

How can I access the ThermoGenesis financial results webcast?

You can access the webcast through ThermoGenesis' investor page on their website.

What technologies does ThermoGenesis focus on?

ThermoGenesis focuses on automated technologies for CAR-T and cell-based therapies.

Where is ThermoGenesis Holdings located?

ThermoGenesis Holdings is located in Rancho Cordova, California.